Advances in clinical chemistry, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Research, Journal Year: 2024, Volume and Issue: 7
Published: Jan. 1, 2024
The intestinal and intratumoral microbiota are closely associated with tumor progression response to antitumor treatments. antibacterial or microenvironment (TME)-modulating approaches have been shown markedly improve efficacy, strategies focused on normalizing the microbial environment rarely reported. Here, we reported development of an orally administered inulin-based hydrogel colon-targeting retention effects, containing hollow MnO 2 nanocarrier loaded chemotherapeutic drug Oxa (Oxa@HMI). On one hand, beneficial bacteria in colon specifically metabolized Oxa@HMI, resulting degradation inulin generation short-chain fatty acids (SCFAs). These SCFAs play a crucial role modulating stimulating immune responses. other matrix underwent microbiota-specific degradation, enabling targeted release production reactive oxygen species acidic TME. In this study, established, for first time, microbiota-targeted delivery system Oxa@HMI that exhibited high efficiency colorectal cancer targeting retention. promoted chemotherapy activated responses by intervening within tissue, providing clinical approach treatment susceptible invasion.
Language: Английский
Citations
21
Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)
Published: Aug. 9, 2024
The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI) tract cancers. role immune checkpoint inhibitors (ICIs), particularly programmed death protein 1 (PD-1) and PD ligand-1 antibodies, has become increasingly pivotal in treatment advanced perioperative GI Currently, anti-PD-1 plus chemotherapy is considered as first-line regimen unselected gastric/gastroesophageal junction adenocarcinoma (G/GEJC), mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC), esophageal (EC). In addition, encouraging performance claudin18.2-redirected chimeric antigen receptor T-cell (CAR-T) therapy later-line cancers brings new hope cell solid tumour treatment. Nevertheless, remains yet precise, researchers are dedicated to further maximising optimising efficacy. This review summarises important research, latest progress, future directions including EC, G/GEJC, CRC.
Language: Английский
Citations
20
Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 179, P. 117302 - 117302
Published: Aug. 19, 2024
Inflammatory bowel disease (IBD), including Crohn's and ulcerative colitis, is a complex disorder with an unknown cause. However, the dysbiosis of gut microbiome has been found to play role in IBD etiology, exacerbated immune responses defective intestinal barrier integrity. The can also be potential biomarker for several diseases, IBD. Currently, conventional treatments targeting pro-inflammatory cytokines pathways IBD-associated do not yield effective results. Other therapies that directly target dysbiotic outcomes are emerging. We review health its as diagnostic, prognostic, therapeutic This explores emerging advancements microbiome-associated alterations IBD, such nanoparticle or encapsulation delivery, fecal microbiota transplantation, nutritional therapies, microbiome/probiotic engineering, phage therapy, mesenchymal stem cells (MSCs), proteins, herbal formulas.
Language: Английский
Citations
16
Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(2), P. 420 - 420
Published: Jan. 12, 2024
The gut microbiota’s influence on human tumorigenesis is a burning topic in medical research. With the new ontological perspective, which considers body and its pathophysiological processes as result of interaction between own eukaryotic cells prokaryotic microorganisms living different niches, great interest has arisen role microbiota carcinogenesis. Indeed, dysbiosis currently recognized cancer-promoting condition, multiple molecular mechanisms have been described by may drive tumor development, especially colorectal cancer (CRC). Metastatic power undoubtedly one most fearsome features neoplastic tissues. Therefore, understanding underlying utmost importance to improve patients’ prognosis. liver frequent target CRC metastasis, evidence reveals that yield an effect diffusion liver, thus defining intriguing facet so-called “gut-liver axis”. In this review, we aim summarize recent data about promoting or preventing hepatic metastasis from CRC, highlighting some potential future therapeutic targets.
Language: Английский
Citations
12
Cancer Management and Research, Journal Year: 2025, Volume and Issue: Volume 17, P. 171 - 192
Published: Jan. 1, 2025
Cancer immunotherapy has transformed cancer treatment in recent years, with immune checkpoint inhibitors (ICIs) emerging as a key therapeutic approach. ICIs work by inhibiting the mechanisms that allow tumors to evade detection. Although have shown promising results, especially solid tumors, patient responses vary widely due multiple intrinsic and extrinsic factors within tumor microenvironment. Emerging evidence suggests gut microbiota plays pivotal role modulating at site may even influence outcomes patients receiving ICIs. This review explores complex interactions between microenvironment, examining how these could impact effectiveness of ICI therapy. Furthermore, we discuss dysbiosis, an imbalance composition, contribute resistance ICIs, highlight microbiota-targeted strategies potentially overcome this challenge. Additionally, studies investigating diagnostic potential profiles patients, considering microbial markers might aid early detection stratification By integrating insights from preclinical clinical studies, aim shed light on microbiome modulation adjunct tool, paving way for personalized approaches optimize outcomes.
Language: Английский
Citations
1
Advanced Science, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 27, 2025
Abstract This article provides an overview of the advancements in application fecal microbiota transplantation (FMT) treating diseases related to intestinal dysbiosis. FMT involves transfer healthy donor into patient's body, aiming restore balance and thereby treat a variety such as recurrent Clostridioides difficile infection (rCDI), inflammatory bowel disease (IBD), constipation, short syndrome (SBS), irritable (IBS). While has shown high efficacy treatment rCDI, further research is needed for its other chronic conditions. elaborates on mechanisms dysbiosis, well discusses key factors influencing effectiveness FMT, including selection, recipient characteristics, protocols, methods assessing microbiota. Additionally, it emphasizes successful FMT. Future should focus optimizing process ensure long‐term safety explore potential broader range medical
Language: Английский
Citations
1
Nature Reviews Clinical Oncology, Journal Year: 2024, Volume and Issue: 21(12), P. 839 - 851
Published: Sept. 24, 2024
Language: Английский
Citations
8
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: June 25, 2024
Depression, projected to be the predominant contributor global disease burden, is a complex condition with diverse symptoms including mood disturbances and cognitive impairments. Traditional treatments such as medication psychotherapy often fall short, prompting pursuit of alternative interventions. Recent research has highlighted significant role gut microbiota in mental health, influencing emotional neural regulation. Fecal transplantation (FMT), infusion fecal matter from healthy donor into patient, emerges promising strategy ameliorate depressive by restoring microbial balance. The microbial-gut-brain (MGB) axis represents critical pathway through which potentially rectify dysbiosis modulate neuropsychiatric outcomes. Preclinical studies reveal that FMT can enhance neurochemicals reduce inflammatory markers, thereby alleviating behaviors. Moreover, shown promise clinical settings, improving gastrointestinal overall quality life patients depression. review highlights gut-brain depression need for further validate long-term safety efficacy FMT, identify specific therapeutic strains, develop targeted modulation strategies. Advancing our understanding could revolutionize treatment, shifting paradigm toward microbiome-targeting therapies.
Language: Английский
Citations
7
International Journal of Colorectal Disease, Journal Year: 2024, Volume and Issue: 39(1)
Published: May 29, 2024
Abstract Background Programmed cell death receptor 1 (PD-1) and programmed ligand (PD-L1) are important immune checkpoint molecules that contribute to tumor evasion. However, the main treatment modalities for patients with early intermediate stage colorectal cancer (CRC) surgery, role of PD-1/PD-L1 inhibitors in these is not yet clear. Therefore, this study aims review progress early- intermediate-stage microsatellite high-instability (MSI-H) stable (MSS) cancer, order provide more options cancer. Materials methods A scoping clinical trial registries ( Clinicaltrials.gov EU registers) PubMed/Medline database trials on Inhibitors middle-stage MSI-H MSS CRC was done up March 2024. Results total 19 related mid-stage MSH-I or were included. Among them, 6 recruiting status, 3 active, completed, terminated, unknown. Of these, 9 involve type CRC, 10 CRC. Preclinical phase I/II predominant, only III trials. In 4 studies combined neoadjuvant therapy, 5 combination therapy. targeted 2 chemotherapy, involves inhibitor immunotherapy, bacterial comprehensive As primary outcome measures, select pathological complete response rates, progression-free survival rate, objective overall disease-free selects percentage participants a dose-limiting toxicity. Conclusion For have shown some therapeutic efficacy, as evidenced by studies. contemporary designs exhibit heterogeneity, relatively few inclusion criteria, use various drug combinations regimens, significant variations reported endpoints. Nevertheless, double-arm, multicenter, randomized controlled still needed confirm efficacy immunotherapy.
Language: Английский
Citations
5
Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 200, P. 104403 - 104403
Published: June 4, 2024
Language: Английский
Citations
5